Candel Therapeutics, Inc.

Quick facts

Phase 3 pipeline

• AdV-tk · Oncology
  AdV-tk is an oncolytic adenovirus expressing herpes simplex virus thymidine kinase that replicates in tumor cells and sensitizes them to ganciclovir, triggering both direct viral lysis and immune activation.
• aglatimagene besadenovec + valacyclovir · Oncology
  Aglatimagene besadenovec is an oncolytic adenovirus expressing IL-12 that replicates in tumor cells and triggers immune activation, combined with valacyclovir (an antiviral) to modulate viral replication kinetics.
• Placebo + valacyclovir · Oncology
  Valacyclovir is an antiviral prodrug that inhibits herpes simplex virus DNA polymerase, while the placebo control allows assessment of the combination's efficacy in a phase 3 trial.

Phase 2 pipeline

• CAN-2409 · Oncology
  CAN-2409 is a T-cell engager that targets the CD3 component of the T-cell receptor.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Candel Therapeutics, Inc. portfolio CI brief
• Candel Therapeutics, Inc. pipeline updates RSS